Research programme: vaccines - FIT Biotech

Drug Profile

Research programme: vaccines - FIT Biotech

Alternative Names: Dengue vaccine - FIT Biotech; Diabetes vaccine - FIT Biotech; Hepatitis C vaccine - FIT Biotech; Malaria vaccine - FIT Biotech; Melanoma vaccine - FIT Biotech; Tuberculosis vaccine - FIT Biotech; Vaccines research programme - FIT Biotech

Latest Information Update: 24 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FIT Biotech
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ebola virus infections; Human papillomavirus infections; Tuberculosis
  • Discontinued Dengue; Diabetes mellitus; Hepatitis C; Malaria; Malignant melanoma

Most Recent Events

  • 23 May 2018 FIT Biotech files two international patent applications for its technology platforms
  • 21 Dec 2004 Preclinical trials in Diabetes mellitus in Finland (unspecified route)
  • 21 Dec 2004 Preclinical trials in Hepatitis C in Finland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top